Solriamfetol for ADHD

Solriamfetol is a dopamine reuptake inhibitor and noradrenaline reuptake inhibitor. It also acts as a serotonin reuptake inhibitor to a negligible extent:¹

• Dopamine IC50: 2.9 μM
• Noradrenaline IC50: 4.4 μM
• Serotonin IC50: > 100

Brand name: Sunosi®

Solriamfetol is approved by the FDA as a drug for narcolepsy.
Initial studies have investigated the possible effect of solriamfetol on ADHD.

Effect:²

• 45% achieved strong or very strong improvement in CGI and at least 25% improvement in AISRS, compared to 6.9% in the placebo group
• greater improvement in total AISRS values from week 3 to week 6
• significantly more frequent improvement of the T-score in the BRIEF-A Global Executive Composite by 0.5 standard deviations
• greater mean change in GAF score (-4.8 compared to -0.3 in the placebo group)
• greater mean change in the MASRS total score
• greater improvement in the ESS score
• PSQI values unchanged

Compatibility:²

• Solriamfetol was well tolerated
• no significant change in
  • Heart rate
  • systolic blood pressure
  • diastolic blood pressure
  • no increase in adverse events
• at least 10 percentage points more frequently than with placebo
  • reduced appetite
  • Headache
  • gastrointestinal complaints
  • Insomnia
  • increased energy consumption
  • cardiovascular and neurological complaints

An individual case report describes a good effect of in a 15-year-old boy with ADHD, in whom atomoxetine, methylphenidate, augmented clonidine and venlaflaine had been ineffective. Within 4 weeks, academic performance had improved remarkably. The inattention subscale of the Vanderbilt test decreased from 8/9 before the treatment to 1/9. There were no side effects.³
Solriamfetol was dosed

• 3 days 37.5 mg in the morning
• 1.5 weeks 75 mg
• 3 days 112.5 mg
• 150 mg